Besponsa™ (inotuzumab ozogamicin) – New orphan drug approval
August 17, 2017 – The FDA announced the approval of Pfizer’s Besponsa (inotuzumab ozogamicin) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
Download PDF
